FDA Launches 'Operation Trial Blazer' to Accelerate Drug Research, Streamline Approvals
AMGN sits 29% above its 52-week low of $267.83 on light trading volume (0.3× avg).
Summary
The U.S. government, via the FDA and NIH, is launching "Operation Trial Blazer" to accelerate early drug research and clinical trials, aiming to cut 6-12 months off safety studies. This initiative seeks to bring drug research back to the U.S. from countries like China and Australia, where companies have found faster regulatory processes. Amgen's EVP of R&D, Jay Bradner, expressed support, noting the potential to reduce operational barriers and allow more trials in regular doctor visits. The reforms include clearer manufacturing guidelines, rolling reviews, a pilot program for faster trials, and reaffirmation that a single high-quality clinical trial can be sufficient for FDA approval. These changes could significantly reduce the time and cost of drug development for pharmaceutical companies like Amgen, improving pipeline efficiency and potentially accelerating market access for new therapies.
At the time of this announcement, AMGN was trading at $344.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $185.8B. The 52-week trading range was $267.83 to $391.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.